Urea 41 NDC 85477-306

NDC codes

FDA NDC Directory

Product NDC (as listed)85477-306Labeler and product segments. Claims need a package NDC.

Product NDC at billing width85477-0306Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
85477-306-27	85477030627	227 g in 1 JAR (85477-306-27)Marketed from Mar 6, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Urea 41
Generic name (nonproprietary): urea 41
Active ingredients: Urea — 41 mg/g
Dosage form: Cream
Route: Topical
Labeler: Oncora Pharma, LLC
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Mar 6, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 85477-306_b128343f-a2d2-416d-b349-d5e39bdc3671SPL ID b128343f-a2d2-416d-b349-d5e39bdc3671SPL set ID ff306984-a52b-48d8-88a8-3a4c72109e63UNII 8W8T17847WUPC 0854770306271

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N485477030627 followed by a unit qualifier and the quantity

Package 85477-0306-27. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 6, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Urea 41% Cream is indicated for debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris, or eschar. It is also indicated for the treatment of hyperkeratotic conditions such as: dry, rough skin dermatitis psoriasis xerosis ichthyosis eczema keratosis pilaris keratosis palmaris keratoderma corns and calluses damaged, ingrown, or devitalized nails

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)